Skip to content

A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.

Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, Yena Lee, Danielle S. Cha, Margarita Shekotikhina, Maj Vinberg, Hartej Gill, Mehala Subramaniapillai, Kevin Kratiuk, Kangguang Lin, R. Ho, Rodrigo B. Mansur, Joshua D. Rosenblat

Journal of Affective Disorders December 29, 2020 DOI: 10.1016/j.jad.2020.12.119 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective analysis Peer reviewed
Sample size 260
Population Patients with treatment-resistant depression receiving IV ketamine
Intervention IV ketamine
Topics Esketamine Ketamine
Key points A 6-item short form of the CADSS shows strong correlation (0.91–0.95) with the full-length CADSS across four ketamine infusions in patients with treatment-resistant depression.

Abstract

Background: Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use.

Methods: Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV ketamine were randomly divided into two datasets. The first dataset (n = 130) was leveraged to develop a brief 6-item version of the CADSS (CADSS-6) based on items most sensitive to ketamine-induced dissociation. The CADSS-6 questions were then applied to the second dataset (n = 130) and the Spearman's correlation between the full-length CADSS and the CADSS-6 were assessed.

Results: The CADSS-6 was developed from questions 1, 2, 6, 7, 15, and 22 from the full length CADSS. There was a strong significant correlation between the CADSS-6 total score and the CADSS total score at infusions 1 (rs(106) = 0.92, p < 0.001), 2 (rs(100) = 0.91, p < 0.001), 3(rs(99) = 0.95, p < 0.001) and 4 (rs(102) = 0.94, p < 0.001).

Limitations: The CADSS-6 was developed using a retrospective data; therefore, the scale remains unvalidated in this population.

Conclusions: The CADSS-6 presented herein was sensitive to dissociation experienced by patients receiving IV ketamine. Overall, the CADSS-6 was strongly correlated at each infusion with the full-length CADSS. While future studies should look to validate the CADSS-6 in a TRD sample, this scale offers clinicians a brief assessment that can be used to characterize symptoms of dissociation.

Comparable studies

Other observational and cohort studies on ketamine, most cited first.

Study Year Design Participants
Taming the Ketamine Tiger Volunteers from a prison population 2010 Observational study n = 20
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans 2017 Observational study
Disruption of Frontal–Parietal Communication by Ketamine, Propofol, and Sevoflurane Surgical patients undergoing induction of anesthesia with intravenous ketamine 2013 Observational cohort n = 30
Do the dissociative side effects of ketamine mediate its antidepressant effects? Treatment-resistant inpatients with major depressive disorder or bipolar disorder 2014 Observational cohort n = 108
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Patients with treatment-resistant major depressive disorder 2012 Observational cohort n = 30

Citations in the library

Cited by 30

and 25 more in the library

Cites 19

and 14 more in the library

Explore topics